|
Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A.
Evaluation of the effect of Alfuprost® MR on detrusor thickness and bladder mass in patients with detrusor hypertrophy caused by benign prostatic hyperplasia
|
№6 / 2023
|
|
D.Yu. Pushkar, O.B. Loran, A.N. Bernikov
The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)
|
№6 / 2022
|
|
A.G. Martov, A.S. Dukhanin, A.N. Bernikov
Current issues in alpha1-adrenergic blocker therapy: integration of pharmacological approach and clinical experience
|
№3 / 2022
|
|
A.I. Novikov, E.S. Shpilenya
Therapeutic efficacy and safety of monotherapy Alfuprost® MR 10 mg/day in clinical practice
|
№2 / 2022
|
|
A.V. Kuzmenko, V.V. Kuzmenko, T.A. Gyaurgiev
Modern possibilities of therapy of a urological patient with concomitant diseases of the cardiovascular system
|
№6 / 2021
|
|
Rasner P.I., Pushkar D.Yu.
The evaluation of efficacy and safety of treatment with dalfaz SR in patients with prostatic adenoma
|
№3 / 2013
|
Русский
